Halogen Bonded Directly To Carbon Patents (Class 514/672)
-
Patent number: 11439589Abstract: Provided are: emulsion eyedrops which have no concern with possible corneal injury induced by a nonionic surfactant, have excellent thermal stability and physical stability and can contain a sparingly water-soluble drug in an increased amount; and an emulsion eyedrops stabilization method. The emulsion eyedrops contain castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5. The emulsion eyedrops stabilization method is characterized by preparing emulsion eyedrops containing castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5.Type: GrantFiled: November 16, 2017Date of Patent: September 13, 2022Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventor: Yasuhiro Mori
-
Patent number: 9402935Abstract: Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogs) and an additive.Type: GrantFiled: May 28, 2013Date of Patent: August 2, 2016Assignee: Lutonix, Inc.Inventor: Lixiao Wang
-
METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS
Publication number: 20150140122Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.Type: ApplicationFiled: June 6, 2013Publication date: May 21, 2015Applicant: INSERM (Institut National de la Sante et de la Rec herche)Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova -
Patent number: 8940779Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.Type: GrantFiled: January 8, 2014Date of Patent: January 27, 2015Assignee: Rohm and Haas CompanyInventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
-
Publication number: 20140194526Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: January 13, 2014Publication date: July 10, 2014Applicant: ACTELION PHARMACEUTICALS LTD.Inventors: Robert ALONSO, Peter A. CROOKS, Mark A. PIMLEY
-
Publication number: 20140155491Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: June 6, 2013Publication date: June 5, 2014Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley
-
Publication number: 20140142193Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of the alkylating agent to the affected skin, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: June 6, 2013Publication date: May 22, 2014Applicant: Actelion Pharmaceuticals, Ltd.Inventors: Robert Alonso, Barry R. Walker, Peter A. Crooks
-
Patent number: 8664278Abstract: A composition for treating psoriasis, mycosis fungoides or alopecia comprising bis-(2-chloroethyl)methylamine or an HX salt and the pharmaceutically acceptable excipient HOCH2CH2OCH2CH2OR79, wherein R79 is a linear alkyl group having 1-6 carbon atoms.Type: GrantFiled: January 7, 2013Date of Patent: March 4, 2014Assignee: Actelion Pharmaceuticals, Ltd.Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley
-
Publication number: 20130310461Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: January 7, 2013Publication date: November 21, 2013Applicant: CEPTARIS THERAPEUTICS, INC.Inventor: Ceptaris Therapeutics, Inc.
-
Patent number: 8513309Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.Type: GrantFiled: September 30, 2011Date of Patent: August 20, 2013Assignee: Oxygen Biotherapeutics, Inc.Inventor: Gerald Klein
-
Patent number: 8501819Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol.Type: GrantFiled: November 17, 2010Date of Patent: August 6, 2013Assignee: Ceptaris Therapeutics, Inc.Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley
-
Patent number: 8501817Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of the alkylating agent to the affected skin, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol.Type: GrantFiled: March 11, 2009Date of Patent: August 6, 2013Assignee: Ceptaris Therapeutics, Inc.Inventors: Robert Alonso, Barry R. Walker, Peter A. Crooks
-
Patent number: 8501818Abstract: Provided are stable compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions.Type: GrantFiled: January 14, 2010Date of Patent: August 6, 2013Assignee: Ceptaris Therapeutics, Inc.Inventors: Robert Alonso, Martin Stogniew, Peter A. Crooks, Mark A. Pimley, David R. Worthen
-
Publication number: 20130184243Abstract: Provided are compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions.Type: ApplicationFiled: July 11, 2012Publication date: July 18, 2013Applicant: Ceptaris Therapeutics, Inc.Inventors: Robert Alonso, Martin Stogniew
-
Publication number: 20120282172Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.Type: ApplicationFiled: May 9, 2012Publication date: November 8, 2012Applicants: Centro de Neurociencias e Biologia Celular, Universidade de CoimbraInventors: João Nuno Sereno de Almeida Moreira, Vera Lúcia Dantas Nunes Caldeira de Moura, Sérgio Paulo de Magalhães Simões, Maria da Conceição Monteiro Pedroso de Lima
-
Publication number: 20120157545Abstract: Provided are methods for treating skin disorders comprising topically applying to the affected skin a composition comprising a nitrogen mustard or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 18, 2011Publication date: June 21, 2012Inventors: Robert ALONSO, Martin Stogniew
-
Publication number: 20120083510Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.Type: ApplicationFiled: September 30, 2011Publication date: April 5, 2012Inventor: Gerald Klein
-
Publication number: 20110171272Abstract: According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic/antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.Type: ApplicationFiled: March 14, 2011Publication date: July 14, 2011Applicant: Boston Scientific Scimed, Inc.Inventors: Jianmin Li, Min-Shyan Sheu, Weenna Bucay-Couto
-
Publication number: 20110130340Abstract: The present invention provides methods of identifying and/or detecting anti-cancer agents. The present invention provides methods of identifying and/or detecting compounds that can activate PARP and/or induce necrosis. The present invention also provides for methods of treating cancer in an individual. The present invention also provides kits for identifying and/or detecting anti-cancer agents.Type: ApplicationFiled: December 6, 2010Publication date: June 2, 2011Inventors: Craig B. Thompson, Wei-Xing Zong
-
Publication number: 20110065803Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: November 17, 2010Publication date: March 17, 2011Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley
-
Publication number: 20110044919Abstract: The invention is directed to a cosmetic composition comprising at least one perfluorinated component and at least one aromatic component, wherein the aromatic component is present in an amount sufficient to compatibilize the fluorinated component in the cosmetic composition; transfer resistant, long wearing or other types of cosmetic or pharmaceutical compositions containing the components and a method for compatibilizing a fluorinated component in a cosmetic composition using an aromatic component, and cosmetic compositions containing at least one perfluorinated amide.Type: ApplicationFiled: August 11, 2008Publication date: February 24, 2011Inventors: Paolo U. Giacomoni, Phillip Cummins, Peter J. Lentini, Manuel L. Tan, John R. Castro, Ismail Ahmed Syed, Garrett William Vanderover
-
Publication number: 20110039943Abstract: Provided are methods for treating skin disorders comprising topically applying to the affected skin a composition comprising a nitrogen mustard or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 24, 2010Publication date: February 17, 2011Inventors: Robert Alonso, Martin Stogniew
-
Patent number: 7872050Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: GrantFiled: March 7, 2006Date of Patent: January 18, 2011Assignee: Yaupon Therapeutics Inc.Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley
-
Patent number: 7838564Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: GrantFiled: August 27, 2009Date of Patent: November 23, 2010Assignee: Yaupon Therapeutics Inc.Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley, Abeer M. Al-Ghananeem
-
Publication number: 20100284905Abstract: The application is based on the observation that tumor stem cell (TSC) replication involves a replicative intermediate configuration wherein a substantial fraction of the TSC genome is present as single-stranded DNA (ssDNA) when bell-shaped nuclei commence separation into two nuclei. During this replicative intermediate configuration large amounts of ssDNA are thus present in the nuclei of cells which the applicant proposes as target for anti-tumor therapy. A method of screening for anti-tumorigenic agents targeting ssDNA and use of such agents in therapy is claimed.Type: ApplicationFiled: June 12, 2008Publication date: November 11, 2010Inventors: Elena V. Gostjeva, William G. Thilly
-
Publication number: 20100183581Abstract: This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.Type: ApplicationFiled: January 7, 2010Publication date: July 22, 2010Applicant: RAPTOR PHARMACEUTICAL INC.Inventors: Richard Beliveau, Michel Demeule, Joseph Yang, Malcolm L. Kennard, Reinhard Gabathuler
-
Patent number: 7749526Abstract: Compounds of formula (I) are described for deterring vermin, wherein R is unbranched or branched C1-C15 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; R1 and R2 are unbranched or branched C1-C12 alkyl, preferably C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; and X and Y, independently of one another, are a straightchain or branched alkylene bridge with 1 to 20 carbon atoms, preferably an alkylene bridge with 1 to 3 carbon atoms, which is unsubstituted or substituted by halogen, cyano or nitro. Furthermore, an essentially non-therapeutical process for deterring vermin is described, which is based on the usage of these compounds, as well as verminrepellent compositions containing these compounds as the active ingredient, and finally the use of these compounds for producing vermin-deterring compositions and their usage in deterring vermin from animals, humans and objects. New compounds within the scope of formula (I) are also described.Type: GrantFiled: December 16, 2003Date of Patent: July 6, 2010Assignee: Novartis AGInventors: Thomas Goebel, Tania Cavaliero, Jacques Bouvier
-
Publication number: 20100152300Abstract: Provided are stable compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions.Type: ApplicationFiled: January 14, 2010Publication date: June 17, 2010Inventors: Robert ALONSO, Martin Stogniew, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin, David R. Worthen
-
Publication number: 20100041767Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: August 27, 2009Publication date: February 18, 2010Applicant: YAUPON THERAPEUTICS, INC.Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin, Abeer M. Al-Ghananeem
-
Publication number: 20100029783Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of the alkylating agent to the affected skin, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: March 11, 2009Publication date: February 4, 2010Inventors: Robert Alonso, Barry R. Walker, Peter A. Crooks
-
Publication number: 20090291049Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.Type: ApplicationFiled: May 22, 2008Publication date: November 26, 2009Applicants: Universidade De Coimbra, Centro De Neurociencias E Biologia CelularInventors: Joao Nuno Sereno de Almeida Moreira, Vera Lucia Dantas Nunes Caldeira de Moura, Sergio Paulo de Magalhaes Simoes, Maria da Conceicao Monteiro Pedroso de Lima
-
Publication number: 20090247645Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of the alkylating agent to the affected skin, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: March 11, 2009Publication date: October 1, 2009Inventors: Robert Alonso, Barry R. Walker, Peter A. Crooks
-
Publication number: 20090062236Abstract: The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.Type: ApplicationFiled: January 29, 2007Publication date: March 5, 2009Applicant: Massachusetts Institute of TechnologyInventors: John M. Essigmann, Robert G. Croy, Kevin J. Yarema, Marshall Morningstar
-
Publication number: 20080286264Abstract: The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either p53 or TBP. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of MUC1 by a cell.Type: ApplicationFiled: February 14, 2006Publication date: November 20, 2008Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventor: Donald W. Kufe
-
Publication number: 20080194699Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: ApplicationFiled: March 14, 2006Publication date: August 14, 2008Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin, Abeer M. Al-Ghananeem
-
Publication number: 20080081078Abstract: Methods of using compounds having certain inhibitory effect to treat cancer are disclosed. More specifically, methods of using myosin light chain kinase inhibitor (MLCK) to treat cancer are disclosed. MLCK inhibitors may cause reduction in MLC-P and induce apoptosis in neoplastic cells and prevent and or inhibit the tumor growth.Type: ApplicationFiled: March 30, 2007Publication date: April 3, 2008Applicant: The Board of Trustees of the University of IllinoisInventor: Primal de Lanerolle
-
Patent number: 7307071Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.Type: GrantFiled: December 3, 2002Date of Patent: December 11, 2007Assignee: Onyx Pharmaceuticals, IncInventors: John F. Lyons, Gideon Bollag
-
Patent number: 7201854Abstract: The present application relates to the use of active compound combinations containing phenolic active compounds and fungicidal active compounds for preserving animal hides and leather.Type: GrantFiled: September 13, 2001Date of Patent: April 10, 2007Assignee: Bayer AktiengesellschaftInventors: Heinz-Joachim Rother, Hartmut Rehbein, Martin Kugler
-
Patent number: 6929685Abstract: The invention relates to methods for preventing the attachment of aquatic organisms to surfaces that are submerged for extension periods of time in water. More particularly, this invention relates to the protection of submerged surfaces with alkylamine derivatives as antifouling agents. The invention is beneficiary for the environment in that it will permit the use of copper- and tin-free paints.Type: GrantFiled: March 27, 2002Date of Patent: August 16, 2005Assignee: Bayer AtiengesellschaftInventors: Daniel Bernard, Jean-Claude Braekman, Gabriele Ferrari, Martin Kugler, Franz Kunisch, Mark Plehiers, Marcel Vos
-
Patent number: 6809120Abstract: Antineoplastic drug modulators are described. The specific modulators referred to are propargylamines which can enhance the cytotoxic effects of antineoplastic drugs on cancer cells while protecting normal cells from damage. The propargylamine modulators can be used to increase the selectivity and effectiveness of conventional antineoplastic drugs, to reduce the unwanted side-effects of cancer chemotherapy, to improve effectiveness of cancer chemotherapy, to improve treatment of cancers for which treatment is otherwise ineffective, to improve therapy of cancers otherwise unresponsive or poorly responsive due to drug-resistance and/or toxicity limited treatment regimens and to render effective chemotherapy for previously untreatable cancers.Type: GrantFiled: April 10, 2002Date of Patent: October 26, 2004Assignee: University of Saskatchewan Technologies Inc.Inventors: R. C. Warrington, I. Alick Paterson, Alan A. Boulton
-
Publication number: 20030213401Abstract: A material and method for treating timber. The material comprises a preservative and a carrier. The carrier is selected such that it remains mobile within the wood and provides for migration of the preservative within the treated wood. By providing a carrier which is mobile within the wood, the timber has a ‘self healing’ effect wherein the carrier/preservative migrates to any freshly cut or exposed surface of the wood to thereby redistribute and treat such a surface within the preservative and hence maintain integrity of a treatment envelope surrounding the wood.Type: ApplicationFiled: June 13, 2003Publication date: November 20, 2003Applicant: Koppers-Hickson Timber Protection Pty LimitedInventor: Peter Ravnor Soundy Cobham
-
Patent number: 6617157Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: where each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H; R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.Type: GrantFiled: December 16, 1998Date of Patent: September 9, 2003Assignee: V.I. Technologies, Inc.Inventors: Edward I. Budowsky, Samuel K. Ackerman, Andrei A. Purmal, Clark M. Edson
-
Patent number: 6569905Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia and atherosclerosis. Combinations disclosed include an cholesteryl ester transfer protein inhibitor combined with a bile acid sequestrant.Type: GrantFiled: December 17, 1999Date of Patent: May 27, 2003Assignee: G.D. Searle, LLCInventors: James A. Sikorski, Kevin C. Glenn
-
Patent number: 6562872Abstract: An emulsion of perfluoroorganic compounds (PFOC) comprises a rapidly eliminable perfluorocarbon (PFC) and a slowly eliminable perfluorinated cyclic tertiary amine, perfluoro-N-4-(methylcyclohexyl)-piperidine and additionally comprises not less then three rapidly eliminable and three slowly eliminable PFOC admixtures with the critical temperature of dissolution in hexane (CTDH) close to that of main PFOC. The PFOC emulsion is stabilized with a polyoxyethylene-polyoxypropylene copolymer having low viscosity to provide high dynamic oxygen capacity and enhancing oxygen delivery to tissues. To prepare the emulsion the stabilizing agent is heated up to 75° C., all components are saturated with carbon dioxide gas to minimize the reactogenicity in intravessel injection as a means of compensation for mass blood loses, perfusion of organs cut of blood flow, treating air-and fat embolism, obliterating vascular injuries of extremities and preventing toxic injuries caused by various xenobiotics.Type: GrantFiled: May 7, 2001Date of Patent: May 13, 2003Assignee: Otkrytoe Aktsionernoe Obschestvo Naucho-Proizvodstven-Naya Firma “Perftoran”Inventors: Evgeny Iliich Maevsky, Genrikh Romanovich Ivanitsky, Kirill Nikolaevich Makarov, Galina Mikhailovna Kulakova, Vladimir Viktorovich Arkhipov, Viktor Vasilievich Moroz, Ljudmila Nikolaevna Starovoitova, Raisa Yakovlevna Senina, Sergei Jurievich Pushkin, Albina Ivanovna Ivashina
-
Publication number: 20030073689Abstract: A composition in the form of an ultrafine oil-in-water emulsion in which the mean size of the oil globules ranges from 50 nm to 1000 nm containing a haloalkynyl derivative, preferably 3-iodo-2-propynyl butylcarbamate.Type: ApplicationFiled: September 26, 2002Publication date: April 17, 2003Applicant: L'OREALInventor: Jerome Senee
-
Publication number: 20030008923Abstract: This invention provides the use of a combination of an mTOR inhibitor and an antineoplastic alkylating agent in the treatment of neoplasms.Type: ApplicationFiled: May 29, 2002Publication date: January 9, 2003Applicant: WyethInventors: Gary Dukart, James Joseph Gibbons
-
Publication number: 20020131967Abstract: A therapeutic agent for myeloma comprising a combined use of a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody. Thus, a therapeutic agent for myeloma comprising anti-IL-6 receptor antibody for use in combination with a nitrogen mustard anticancer agent; a therapeutic agent for myeloma comprising a nitrogen mustard anticancer agent for use in combination with anti-IL-6 receptor antibody; and a therapeutic agent for myeloma comprising a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody.Type: ApplicationFiled: March 15, 2002Publication date: September 19, 2002Inventors: Akito Nakamura, Kenichi Akamatsu
-
Patent number: 6444230Abstract: Composition in the form of an aqueous solution, useful for disinfecting hard surfaces comprises: a) from 0.0005% to 20% by weight of peracetic acid, b) from 0.001% to 45% by weight of acetic acid, c) from 0.001% to 35% by weight of hydrogen peroxide, d) from 0.0001% to 2% by weight of at least one compound of formula (I) (R1)(R2)(R3)N→O (I) e) if desired, up to 2.5% by weight of at least one nonionic surfactant, and wherein f) the weight ratio between the compound of formula (I) and the peracetic acid is less than or equal to 1, and in that g) the weight ratio between the nonionic surfactant and the peracetic acid is less than or equal to 0.2.Type: GrantFiled: November 20, 2000Date of Patent: September 3, 2002Assignees: Chemoxal SA, Societe d'Exploitation de Produits pour les Industries Chimiques SeppicInventors: Catherine Hamon Godin, Yves Gouges, Daniel Le Rouzic
-
Publication number: 20020106391Abstract: Aqueous dispersions of 2-(4-thiazolyl)-benzimidazole (TBZ), alone or in combination with 1,2-dibromo-2,4-dicyanobutane (DBDCB), and processes for making the same, are disclosed. These processes generally comprise mixing a xanthan gum with water, adding TBZ and mixing until uniform. DBDCB dispersions are prepared by mixing xanthan gum with water, adding DBDCB, maintaining the mixture at a temperature below about 40° C., grinding the mixture and mixing until uniform. The TBZ and DBDCB dispersions are then blended to prepare a dispersion containing both active ingredients. A method for inhibiting microbial growth utilizing these dispersions is also claimed.Type: ApplicationFiled: May 11, 2000Publication date: August 8, 2002Inventors: David H Bialosky, Jodi L Martin
-
Patent number: 6414179Abstract: Inhibitors of the cytosolic phospholipase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where X, Z, R1, R2, R3, R4, Ra and Rb are as defined in the specification.Type: GrantFiled: March 23, 2001Date of Patent: July 2, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Jacques Banville, Anne Marinier, Yonghua Gai, Serge Plamondon, Stephan Roy, Neelakantan Balasubramanian